PATENT CLAIM ANALYSIS

Application Number: 16195026
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-07
Patent Classification: ["514", "274000"]

Abstract:
The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

Claim (Index 68):
A method of treating a disease, wherein said disease is selected from hematological cancer, sarcoma, liver cancer, lung cancer, nervous system cancer, breast cancer, ovarian cancer, head and neck cancer, myelofibrosis, gastrointestinal cancer, genitourinary tract cancer, skin cancer and thyroid cancer, comprising administering to a patient a therapeutically effective amount of a compound selected from:\n 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl)cyclopentanecarboxylic acid, 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, 1-{[4-({[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino}methyl)-4-(methoxymethyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, or 1-{[4-(ethoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl)cyclobutanecarboxylic acid, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 86.0
- Percentile: 98.0
- Lexical Diversity: 1.0
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14620903', '15355995', '15285792', '15970954', '14620950']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8432907676495927
- 35 USC 102 Novelty (BERT): 0.6199937135690451
- Combined Prediction Score: 0.8209610622415379
- Mean Citation Score: 579.3148279999998
- Max Citation Score: 609.79474
- Similarity Product: 510.4060558054472

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test